ABSTRACT
There have been encouraging results for the development of an effective HIV vaccine. However, many questions remain regarding the quality of immune responses and the role of mucosal antibodies. We addressed some of these issues by using a simian immunodeficiency virus (SIV) DNA vaccine adjuvanted with plasmid-expressed mucosal chemokines combined with an intravaginal SIV challenge in rhesus macaque (RhM) model. We previously reported on the ability of CCR9 and CCR10 ligand (L) adjuvants to enhance mucosal and systemic IgA and IgG responses in small animals. In this study, RhMs were intramuscularly immunized five times with either DNA or DNA plus chemokine adjuvant delivered by electroporation followed by challenge with SIVsmE660. Sixty-eight percent of all vaccinated animals (P<0.01) remained either uninfected or had aborted infection compared with only 14% in the vaccine naïve group. The highest protection was observed in the CCR10L chemokines group, where six of nine animals had aborted infection and two remained uninfected, leading to 89% protection (P<0.001). The induction of mucosal SIV-specific antibodies and neutralization titers correlated with trends in protection. These results indicate the need to further investigate the contribution of chemokine adjuvants to modulate immune responses and the role of mucosal antibodies in SIV/HIV protection.
Subject(s)
AIDS Vaccines/administration & dosage , Antibodies, Viral/biosynthesis , Chemokines/immunology , Immunity, Mucosal/drug effects , Simian Acquired Immunodeficiency Syndrome/prevention & control , Vaccines, DNA/administration & dosage , AIDS Vaccines/genetics , AIDS Vaccines/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Chemokines/administration & dosage , Chemokines/genetics , Female , Immunity, Cellular/drug effects , Ligands , Macaca mulatta , Plasmids/chemistry , Plasmids/immunology , Receptors, CCR/genetics , Receptors, CCR/immunology , Receptors, CCR10/genetics , Receptors, CCR10/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/drug effects , Simian Immunodeficiency Virus/immunology , Vaccination , Vaccines, DNA/genetics , Vaccines, DNA/immunology , Vagina/drug effects , Vagina/immunology , Vagina/virologyABSTRACT
Leptospirosis is a bacterial zoonotic disease caused by an infection with a spirochete belonging to the genus Leptospira. In animals, leptospirosis displays a wide range of pathologies, including fever, abortion, icterus, and uveitis. Conversely, infection in humans is associated with multi-organ injury, resulting in an increased rate of fatalities. Pathogenic leptospires are able to translocate through cell monolayers at a rate significantly greater than that of non-pathogenic leptospires. Thus, vaccine approaches have been focused on targeting bacterial motility, lipopolysaccharides (LPSs), lipoproteins, outer-membrane proteins (OMPs) and other potential virulence factors. Previous studies have indicated that leptospiral proteins elicit long-lasting immunological memory in infected humans. In the study reported here, the efficacy of a synthetic consensus DNA vaccine developed against the Leptospira membrane lipoprotein LipL45 was tested. After in vivo electroporation (EP) mediated intramuscular immunization with a synthetic LipL45 DNA vaccine (pLipL45) immunized mice developed a significant cellular response along with the development of anti-LipL45-specific antibodies. Specifically, the pLipL45 vaccine induced a significant Th1 type immune response, indicated by the higher production of IL-12 and IFN-γ cytokines. The results presented here are the first demonstration that a LipL45 based DNA immunogen has potential as a anti-Leptospira vaccine.
Subject(s)
Bacterial Outer Membrane Proteins/immunology , Bacterial Vaccines/immunology , Leptospirosis/prevention & control , Lipoproteins/immunology , Vaccines, DNA/immunology , Animals , Antibodies, Bacterial/blood , Bacterial Outer Membrane Proteins/genetics , Bacterial Vaccines/administration & dosage , Bacterial Vaccines/genetics , Electroporation , Female , Injections, Intramuscular , Interferon-gamma/metabolism , Interleukin-12/metabolism , Leukocytes, Mononuclear/immunology , Lipoproteins/genetics , Mice, Inbred BALB C , Th1 Cells/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunologyABSTRACT
Interleukin-15 (IL-15) is a common γ-chain cytokine that has a significant role in the activation and proliferation of T and NK cells and holds great potential in fighting infection and cancer. We have previously shown that bioactive IL-15 in vivo comprises a complex of the IL-15 chain with the soluble or cell-associated IL-15 receptor alpha (IL-15Rα) chain, which together form the IL-15 heterodimer. We have generated DNA vectors expressing the heterodimeric IL-15 by optimizing mRNA expression and protein trafficking. Repeated administration of these DNA plasmids by intramuscular injection followed by in vivo electroporation in rhesus macaques resulted in sustained high levels of IL-15 in plasma, with no significant toxicity. Administration of DNAs expressing heterodimeric IL-15 also resulted in an increased frequency of NK and T cells undergoing proliferation in peripheral blood. Heterodimeric IL-15 led to preferential expansion of CD8(+)NK cells, all memory CD8(+) T-cell subsets and effector memory CD4(+) T cells. Expression of heterodimeric IL-15 by DNA delivery to the muscle is an efficient procedure to obtain high systemic levels of bioactive cytokine, without the toxicity linked to the high transient cytokine peak associated with protein injection.
Subject(s)
Cell Proliferation , Interleukin-15/biosynthesis , Killer Cells, Natural/physiology , T-Lymphocytes/physiology , Animals , Cells, Cultured , Electroporation , Gene Expression , Genetic Therapy , Injections, Intramuscular , Interleukin-15/genetics , Macaca mulatta , TransfectionABSTRACT
Melanoma is the most deadly type of skin cancer, constituting annually â¼ 75% of all cutaneous cancer-related deaths due to metastatic spread. Currently, because of metastatic spread, there are no effective treatment options for late-stage metastatic melanoma patients. Studies over the past two decades have provided insight into several complex molecular mechanisms as to how these malignancies evade immunological control, indicating the importance of immune escape or suppression for tumor survival. Thus, it is essential to develop innovative cancer strategies and address immune obstacles with the goal of generating more effective immunotherapies. One important area of study is to further elucidate the role and significance of myeloid-derived suppressor cells (MDSCs) in the maintenance of the tumor microenvironment. These cells possess a remarkable ability to suppress immune responses and, as such, facilitate tumor growth. Thus, MDSCs represent an important new target for preventing tumor progression and escape from immune control. In this study, we investigated the role of MDSCs in immune suppression of T cells in an antigen-specific B16 melanoma murine system utilizing a novel synthetic tyrosinase (Tyr) DNA vaccine therapy in both prophylactic and therapeutic models. This Tyr vaccine induced a robust and broad immune response, including directing CD8 T-cell infiltration into tumor sites. The vaccine also reduced the number of MDSCs in the tumor microenvironment through the downregulation of monocyte chemoattractant protein 1, interleukin-10, CXCL5 and arginase II, factors important for MDSC expansion. This novel synthetic DNA vaccine significantly reduced the melanoma tumor burden and increased survival in vivo, due likely, in part, to the facilitation of a change in the tumor microenvironment through MDSC suppression.
Subject(s)
Cancer Vaccines/immunology , Melanoma/immunology , Melanoma/therapy , Monophenol Monooxygenase/immunology , Myeloid Cells/immunology , Vaccines, DNA/immunology , Animals , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cancer Vaccines/administration & dosage , Cytokines/metabolism , Disease Models, Animal , Female , Humans , Immunity, Cellular , Immunity, Humoral , Immunization , Immunomodulation , Melanoma/genetics , Melanoma/mortality , Melanoma/pathology , Melanoma/prevention & control , Melanoma, Experimental , Mice , Monophenol Monooxygenase/antagonists & inhibitors , Monophenol Monooxygenase/genetics , Myeloid Cells/metabolism , T-Cell Antigen Receptor Specificity , Tumor Burden/immunology , Tumor Microenvironment , Vaccines, DNA/administration & dosageABSTRACT
There are well over a quarter of a billion chronic hepatitis B virus (HBV) carriers across the globe. Most carriers are at high risk for development of liver cirrhosis and subsequent progression to hepatocellular carcinoma. It is therefore imperative to develop new approaches for immunotherapy against this infection. Antibodies and cytotoxic T cells to different HBV antigens are believed to be important for reducing viral load and clearing HBV-infected cells from the liver. Some of the major challenges facing current vaccine candidates have been their inability to induce both humoral and cellular immunity to multiple antigenic targets and the induction of potent immune responses against the major genotypes of HBV. In this study, highly optimized synthetic DNA plasmids against the HBV consensus core (HBc) and surface (HBs) antigens genotypes A and C were developed and evaluated for their immune potential. These plasmids, which encode the most prevalent genotypes of the virus, were observed to individually induce binding antibodies to HBs antigens and drove robust cell-mediated immunity in animal models. Similar responses to both HBc and HBs antigens were observed when mice and non-human primates were inoculated with the HBc-HBs cocktails. In addition to the cytotoxic T lymphocyte activities exhibited by the immunized mice, the vaccine-induced responses were broadly distributed across multiple antigenic epitopes. These elements are believed to be important to develop an effective therapeutic vaccine. These data support further evaluation of multivalent synthetic plasmids as therapeutic HBV vaccines.
Subject(s)
Antibody Formation/genetics , Cytotoxicity, Immunologic/genetics , Genotype , Hepatitis B Core Antigens/genetics , Hepatitis B Surface Antigens/genetics , Hepatitis B virus/genetics , Vaccines, DNA/genetics , Animals , Antibody Formation/immunology , Cell Line , Cytokines/metabolism , Cytotoxicity, Immunologic/immunology , Epitopes, T-Lymphocyte/immunology , Female , Gene Order , Hepatitis B/immunology , Hepatitis B/prevention & control , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B virus/immunology , Humans , Immunity, Cellular , Immunity, Humoral , Liver/immunology , Liver Function Tests , Macaca mulatta , Mice , Plasmids/genetics , Spleen/immunology , T-Lymphocytes, Cytotoxic/immunology , Vaccination , Vaccines, DNA/immunologyABSTRACT
A vaccine candidate that elicits humoral and cellular responses to multiple sporozoite and liver-stage antigens may be able to confer protection against Plasmodium falciparum malaria; however, a technology for formulating and delivering such a vaccine has remained elusive. Here, we report the preclinical assessment of an optimized DNA vaccine approach that targets four P. falciparum antigens: circumsporozoite protein (CSP), liver stage antigen 1 (LSA1), thrombospondin-related anonymous protein (TRAP), and cell-traversal protein for ookinetes and sporozoites (CelTOS). Synthetic DNA sequences were designed for each antigen with modifications to improve expression and were delivered using in vivo electroporation (EP). Immunogenicity was evaluated in mice and nonhuman primates (NHPs) and assessed by enzyme-linked immunosorbent assay (ELISA), gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assay, and flow cytometry. In mice, DNA with EP delivery induced antigen-specific IFN-γ production, as measured by ELISpot assay and IgG seroconversion against all antigens. Sustained production of IFN-γ, interleukin-2, and tumor necrosis factor alpha was elicited in both the CD4(+) and CD8(+) T cell compartments. Furthermore, hepatic CD8(+) lymphocytes produced LSA1-specific IFN-γ. The immune responses conferred to mice by this approach translated to the NHP model, which showed cellular responses by ELISpot assay and intracellular cytokine staining. Notably, antigen-specific CD8(+) granzyme B(+) T cells were observed in NHPs. Collectively, the data demonstrate that delivery of gene sequences by DNA/EP encoding malaria parasite antigens is immunogenic in animal models and can harness both the humoral and cellular arms of the immune system.
Subject(s)
Antigens, Protozoan/immunology , DNA, Protozoan/immunology , Liver/parasitology , Plasmids/genetics , Plasmodium falciparum/physiology , Sporozoites/immunology , Animals , Cell Line , DNA, Protozoan/genetics , Female , Immunity, Cellular , Immunity, Humoral , Macaca mulatta , Malaria, Falciparum/immunology , Malaria, Falciparum/parasitology , Mice , Mice, Inbred BALB CABSTRACT
The magnitude of the immune response to a DNA vaccine depends on three criteria--the optimized vector design, the use of a suitable adjuvant and the successful delivery and subsequent expression of the plasmid in the target tissue. In vivo electroporation (EP) has proved to be particularly effective in efficiently delivering DNA immunogens to the muscle and the skin, and indeed several devices have entered into human clinical trials. Here, we report on a novel concept of DNA delivery to the dermal tissue using a minimally invasive EP device, which is powered using low-voltage parameters. We show that this prototype device containing a novel 4 × 4-electrode array results in robust and reproducible transfection of dermal tissue and subsequent antigen expression at the injection site. Using DNA encoding for NP and M2e influenza antigens, we further show induction of potent cellular responses in a mouse model as measured by antigen-specific T-cell ELISpot assays. Importantly, 100% of the immunized animals were protected when challenged with VN/1203/04 (H5N1) strain of influenza. We have also extended our findings to a guinea-pig model and demonstrated induction of HI titers greater than 1:40 against a pandemic novel H1N1 virus showing proof of concept efficacy for DNA delivery with the prototype device in a broad spectrum of species and using multiple antigens. Finally, we were able to generate protective HI titers in macaques against the same novel H1N1 strain. Our results suggest that the minimally invasive dermal device may offer a safe, tolerable and efficient method to administer DNA vaccinations in a prophylactic setting, and thus potentially represents an important new option for improved DNA vaccine delivery in vivo.
Subject(s)
Electroporation/instrumentation , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H5N1 Subtype/immunology , Influenza Vaccines/administration & dosage , Transfection/instrumentation , Vaccines, DNA/administration & dosage , Animals , Antigens, Viral/genetics , Electrodes , Enzyme-Linked Immunospot Assay , Female , Guinea Pigs , Influenza Vaccines/immunology , Mice , Mice, Inbred BALB C , Vaccines, DNA/immunologyABSTRACT
BACKGROUND AND PURPOSE: VGX-1027 is a novel, low molecular weight, immunomodulatory compound that has shown efficacy against a variety of immuno-inflammatory disease models in animals including autoimmune diabetes in NOD mice, collagen-induced arthritis and chemically induced inflammatory colitis. Here, we have studied the effects of VGX-1027 on the development of endotoxin-induced uveitis (EIU) in male Lewis rats, as a model of inflammatory ocular diseases in humans. EXPERIMENTAL APPROACH: EIU was induced by a single footpad injection of 200 microg lipopolysaccharide (LPS). Groups of rats were treated with either VGX-1027 (25 mg kg(-1)) or its vehicle at different time points (30 min, 6 h or 12 h) after the challenge with LPS or, as positive control, with dexamethasone. The rats were killed within 16 h after LPS challenge, and the eyes and aqueous humor were collected to study serological, immunological and histological signs of EIU. KEY RESULTS: The rats treated with VGX-1027 within 6 h after LPS challenge exhibited milder clinical, histological and laboratory signs of EIU than those treated with vehicle. CONCLUSION AND IMPLICATIONS: This study provides the first evidence that systemic treatment with VGX-1027 counteracts the uveitis-inducing effect of LPS in rats and suggests that this drug may have potential in the treatment of immuno-inflammatory conditions of the eye in humans.
Subject(s)
Acetates/therapeutic use , Immunologic Factors/therapeutic use , Lipopolysaccharides/administration & dosage , Oxazoles/therapeutic use , Uveitis/drug therapy , Acetates/administration & dosage , Acetates/pharmacology , Animals , Aqueous Humor/cytology , Aqueous Humor/drug effects , Aqueous Humor/immunology , Ciliary Body/drug effects , Ciliary Body/immunology , Ciliary Body/pathology , Disease Models, Animal , Eye Proteins/immunology , Immunohistochemistry , Immunologic Factors/administration & dosage , Immunologic Factors/pharmacology , Iris/drug effects , Iris/immunology , Iris/pathology , Male , Oxazoles/administration & dosage , Oxazoles/pharmacology , Rats , Rats, Inbred Lew , Transcription Factor RelA/immunology , Tumor Necrosis Factor-alpha/immunology , Uveitis/chemically induced , Uveitis/immunology , Uveitis/pathologyABSTRACT
Abstract Some evidence and considerations suggest that RNA minihelices based on the acceptor-TΨC stem-loop of tRNAs are the historical, more ancient part of the tRNA structure. These minihelices are substrates for aminoacylation by tRNA synthetases. In the transition from the RNA world to the theatre of proteins, aminoacyl minihelices may have had a role in early systems of peptide synthesis. Such systems would require bringing together aminoacyl groups into close proximity in order for peptide bonds to form. Here we report the design of RNA scaffolds based on pieces of the structure of the P4-P6 domain of the Tetrahymena ribozyme. RNA minihelices were incorporated into these scaffolds and the resulting RNAs could be enzymatically aminoacylated. The RNA scaffolds containing the minihelix-like pieces associated spontaneously to create the presumptive P4-P6 structure and thereby bring together the substrates for aminoacylation. Thus, peptide synthesis with associating RNA scaffolds that contain minihelix-like motifs appears plausible.
Subject(s)
Nucleic Acid Conformation , RNA , Base Sequence , RNA/chemistry , RNA, TransferABSTRACT
RNA minihelices that recreate the amino acid acceptor domain of the two-domain L-shaped tRNA molecule are substrates for specific aminoacylation by tRNA synthetases. Some lines of evidence suggest that this domain arose independently of and predated the second, anticodon-containing domain. With puromycin and a minihelix charged with alanine, we show here efficient 50S ribosome catalyzed peptide synthesis. The aminoacyl minihelix is as active as aminoacyl tRNA in the synthetic reaction. The high efficiency of the charged minihelix is due to a relatively strong interaction with the 50S particle. In contrast, an aminoacyl RNA fragment that recreates the 3'-side of the tRNA acceptor stem has a much weaker interaction with the 50S particle. These results are consistent with the minihelix domain being the major loci for tRNA interactions with the 50S ribosome. They may also have implications for the historical development of RNA-based systems of peptide synthesis.
Subject(s)
Nucleic Acid Conformation , Peptide Biosynthesis , RNA, Ribosomal/metabolism , RNA, Transfer, Ala/metabolism , Acylation , Alanine-tRNA Ligase/metabolism , Catalysis , Chromatography, Thin Layer , Oligopeptides/metabolism , Peptidyl Transferases/metabolism , Puromycin/analogs & derivatives , Puromycin/biosynthesis , RNA, Ribosomal/chemistry , RNA, Transfer, Ala/chemistry , Substrate Specificity , Transfer RNA AminoacylationABSTRACT
RNA microhelices that recreate the acceptor stems of transfer RNAs are charged with specific amino acids. Here we identify a two-helix pair in alanyl-tRNA synthetase that is required for RNA microhelix binding. A single point mutation at an absolutely conserved residue in this motif selectively disrupts RNA binding without perturbation of the catalytic site. These results, and findings of similar motifs in the proximity of the active sites of other tRNA synthetases, suggest that two-helix pairs are widespread and provide a structural framework important for contacts with bound RNA substrates.
Subject(s)
Alanine-tRNA Ligase/chemistry , Protein Structure, Secondary , RNA, Transfer, Ala/chemistry , Alanine-tRNA Ligase/genetics , Amino Acid Sequence , Arginine/chemistry , Aspartic Acid/chemistry , Binding Sites , Conserved Sequence , Escherichia coli/enzymology , Kinetics , Molecular Sequence Data , Nucleic Acid ConformationABSTRACT
Phenanthrenequinone diimine (phi) complexes of rhodium(III) bearing appended peptides have been prepared using two complementary solid phase synthetic strategies. The first method involves the direct coupling of the coordinatively saturated rhodium complex containing a pendant carboxylate to the N-terminus of a resin-bound peptide, in a manner analogous to the chain-elongation step in solid phase peptide synthesis. The second involves coupling a bidentate chelator containing the pendant carboxylate to the resin-bound peptide, followed by coordination of [Rh(phi)2]3+ to the bidentate chelator attached to the peptide. Peptides of length 5-30 residues have been covalently attached to rhodium complexes in 5-18% yield using both methods. Despite the low overall yields, the regioselective modification of the peptide chain afforded by these strategies is a distinct advantage over solution phase methods. With coordination complexes which are stable to peptide deprotection and cleavage conditions from the resin, the solid phase synthetic strategies are convenient to apply. Amino acid analysis, electronic spectroscopy, and circular dichroism confirm the presence of the two components in the metal-peptide chimeras; the metal-peptide complexes exhibit the combined spectral properties of the parent metal complex and the appended peptide. Significantly, plasma desorption mass spectrometry reveals a novel pattern of peptide fragmentation for the metal-peptide chimeras that is not observed in the absence of the tethered metal complex; this fragmentation facilitates the sequence analysis of the appended peptide. Thus, metal-peptide chimeras may be conveniently prepared using solid phase methodologies, and features of coordination chemistry may be exploited for new peptide design and analysis.